Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Rhea-AI Summary
Tenax Therapeutics (Nasdaq: TENX) announced that President & CEO Chris Giordano will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. A live and archived webcast will be available via the company’s investor relations webpage.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | Phase 3 trial results | Negative | -89.8% | Primary and key secondary endpoints were not met in the LEVEL trial |
| Jul 31 | 2Q26 earnings report | Negative | -9.3% | Quarterly net loss and research spending increased year over year |
| Jul 02 | Inducement grants | Negative | +5.2% | Options covering 160,000 shares were granted to three newly hired employees |
| Jul 02 | Conference presentation | Neutral | +16.3% | Phase 3 LEVEL data received a late-breaking ESC Congress presentation slot |
| May 12 | 1Q26 earnings report | Neutral | +1.8% | Cash runway and Phase 3 program updates accompanied quarterly financial results |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Negative reactions followed the Phase 3 result and Q2 report, while the earlier presentation announcement rose 16.33%; reactions were mixed across corporate updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET.
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
